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Abstract
Background: Epigenetic data could help identify risk factors for orofacial clefts, either by revealing a causal role for
epigenetic mechanisms in causing clefts or by capturing information about causal genetic or environmental factors.
Given the evidence that different subtypes of orofacial cleft have distinct aetiologies, we explored whether children
with different cleft subtypes showed distinct epigenetic profiles.
Methods: In whole-blood samples from 150 children from the Cleft Collective cohort study, we measured DNA
methylation at over 450,000 sites on the genome. We then carried out epigenome-wide association studies (EWAS)
to test the association between methylation at each site and cleft subtype (cleft lip only (CLO) n = 50; cleft palate
only (CPO) n = 50; cleft lip and palate (CLP) n = 50). We also compared methylation in the blood to methylation in
the lip or palate tissue using genome-wide data from the same 150 children and conducted an EWAS of CLO
compared to CLP in lip tissue.
Results: We found four genomic regions in blood differentially methylated in CLO compared to CLP, 17 in CPO
compared to CLP and 294 in CPO compared to CLO. Several regions mapped to genes that have previously been
implicated in the development of orofacial clefts (for example, TBX1, COL11A2, HOXA2, PDGFRA), and over 250
associations were novel. Methylation in blood correlated with that in lip/palate at some regions. There were 14
regions differentially methylated in the lip tissue from children with CLO and CLP, with one region (near KIAA0415)
showing up in both the blood and lip EWAS.
Conclusions: Our finding of distinct methylation profiles in different orofacial cleft (OFC) subtypes represents a
promising first step in exploring the potential role of epigenetic modifications in the aetiology of OFCs and/or as
clinically useful biomarkers of OFC subtypes.
Keywords: Cleft Collective, DNA methylation, Epigenome-wide association study, EWAS, Cleft lip, Cleft palate,
Orofacial clefts
Background
Orofacial clefts (OFCs) are a set of common birth defects
that affect roughly 15 in every 10,000 births in Europe [1].
There are three main subtypes of OFC: cleft palate only
(CPO), cleft lip only (CLO) and cleft lip with cleft palate
(CLP) (Fig. 1). Non-syndromic cases, which comprise
around 70% of cases of cleft lip with or without cleft pal-
ate, have a complex aetiology involving both genetic and
environmental factors [2].
A child born with an OFC may face difficulties with
feeding, speech, dental development, hearing and social
adjustment. At considerable health, emotional and finan-
cial costs, they undergo surgery in the first year of life
and many need additional surgical procedures later in
life. They may experience low self-esteem, psychosocial
problems and poor educational attainment, and the con-
dition can harm the emotional wellbeing of the whole
family [2–4].
In 2012, the James Lind Alliance identified the top 10
priorities in OFC research, which includes (1) identifying
the genetic and environmental causes of OFCs and (2)* Correspondence: gemma.sharp@bristol.ac.uk1MRC Integrative Epidemiology Unit, School of Oral and Dental Sciences,
University of Bristol, Bristol, England
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identifying strategies to improve diagnosis of CPO. Epi-
genetic data might help to address both of these.
Firstly, given the key role of epigenetic processes such
as DNA methylation in embryonic development, we and
others have hypothesised that aberrant epigenetic mech-
anisms might play a role in causing OFCs [2, 5, 6]. This
hypothesis has been supported by data suggesting an im-
portant role for DNA methylation and other epigenetic
processes in regulating normal orofacial development
and OFCs in mice [7–12], but published epigenetic data
for OFCs in humans is lacking. The three major subtypes
of OFC (CPO, CLO, CLP) appear to be aetiologically dis-
tinct, for example, lip and palate formation occur at differ-
ent times during embryogenesis, and there is a higher risk
of familial recurrence of the same subtype compared with
risk of recurrence of a different subtype [13, 14]. There-
fore, if epigenetic mechanisms play a causal role in OFC
aetiology, the precise role may differ by subtype. Secondly,
regardless of whether epigenetics plays any causal role in
OFC development, epigenetic data ‘captures’ information
about the underlying genetic architecture and historical
prenatal environmental exposures and could therefore be
a useful measure of genetic and prenatal environmental
influences that do cause OFCs. Again, we might expect
these epigenetic indicators to differ by subtype, reflecting
differential influence by different risk factors. Thirdly, if
epigenetic profiles differ by OFC subtype, epigenetic mea-
sures could be developed into a biomarker to improve
diagnosis of OFCs, either pre- or postnatally. This would
be particularly useful for diagnosing CPO, which is often
undetected on ultrasound and can go undiagnosed after
birth, resulting in impaired feeding and growth, poorer
outcomes and distress for families [15].
Additionally, epigenetic data could be useful in studying
later-life outcomes associated with OFCs. For example,
DNA methylation in cord blood has been associated with
childhood IQ [16], so future studies could explore
whether methylation mediates reported associations
between OFCs and poor educational attainment [4].
Alternatively, even in the absence of a mechanistic role
for epigenetic processes, epigenetic data might predict
later-life outcomes caused by genetic and/or environ-
mental factors.
As a first step towards exploring the potential role of
epigenetic modifications in either causing or predicting
various OFC phenotypes and downstream outcomes, we
were interested in whether children with different sub-
types of OFCs have distinct DNA methylation profiles.
In the Cleft Collective birth cohort study, we studied
DNA methylation in whole blood and lip/palate tissue
from non-syndromic children with CLO, CPO and CLP.
Methods
Participants
Participants were children from the United Kingdom en-
rolled in the Cleft Collective birth cohort study between
2013 and 2016 [17, 18]. Families of a child with an OFC
were invited to take part soon after the child was born.
Demographic and lifestyle information for both parents
was collected via questionnaire. Blood and discarded lip/
palate samples were collected at time of surgery to repair
the OFC. Additional details on the surgery and OFC
were collected on a surgical form. For the purposes of
the current study, a sample of 150 believed-to-be non-
syndromic children (with no other known anomalies)
was randomly selected. The sample was stratified by
OFC subtype (CLO, CPO, CLP) resulting in 50 children
per group.
Classification of OFC
Details on the cleft phenotype were collected from surgi-
cal forms completed at the time of operation and from
parental questionnaires. Surgeons recorded the phenotype
using either the LAHSAL or LAHSHAL classification
[19], which was condensed to CPO, CLP or CLO for the
purposes of this study. Parents used this simplified classifi-
cation of subtype (CPO, CLP or CLO). Where data were
Fig. 1 Orofacial cleft subtypes. Orofacial clefts are traditionally categorised as either cleft lip only (CLO; a, b), cleft palate only (CPO; c–f) or cleft lip
with cleft palate (CLP; g–j). Further subtyping can be made according to laterality and whether the soft and/or hard palate is affected. The dark
bars represent the cleft
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available from both sources, we compared the reported
subtype and found no discrepancies.
Other variables
The child’s age at biological sample collection was calcu-
lated from the child’s date of birth to the date of surgery.
We were interested in whether children with different
OFC subtypes have different rates of development, so we
also predicted the child’s ‘epigenetic age’ using blood
methylation data and the method developed by Horvath
[20] (discussed in more details in Additional file 1). ‘Age
acceleration’ was calculated as the residuals from a linear
regression of epigenetic age on actual age at sample col-
lection. A positive value corresponds to an individual
whose epigenetic age is ahead of their actual age, and vice-
versa. Sex was initially assumed by staff at the Cleft Col-
lective using the child’s name and later confirmed by par-
ental questionnaires, where available, and NHS Digital
data if explicit consent was held. Mothers self-reported
how much they smoked around the time of conception,
and this was classified for the purposes of this study as
any or no smoking around conception. Additionally, a
score to predict in utero/early-life smoke exposure was
calculated from the child’s blood DNA methylation data.
The score was calculated as previously described [21]
using a weighted sum of methylation beta values at 26
maternal-smoking-associated methylation sites identified
in cord blood [22]. The efficacy of this score for predicting
maternal smoking is discussed in Additional file 1. Infor-
mation on the mother’s occupation was dichotomised as
either non-manual skilled work or manual/unskilled/no
work. Information on the mother’s education was dichoto-
mised as achieving a university degree/above or not
achieving a university degree. Information on parity was
dichotomised for this study as no previous children or one
or more previous children. Maternal and paternal age in
years were reported by the mother and treated as continu-
ous variables. Maternal and paternal ethnicity were re-
ported by the mother and used to deduce child ethnicity
as white or other. For each model, surrogate variables
were generated using the sva package [23, 24] in R [25] to
capture residual variation associated with technical batch
and cellular heterogeneity. The number of surrogate vari-
ables (10) was estimated by the sva algorithm using the
methylation data and the model matrices. Blood cell type
proportions were also estimated using the Houseman
method [26, 27] for use in a sensitivity analysis (there is
no appropriate reference panel to use the Houseman
method to estimate cell type proportions for the lip/palate
tissue).
DNA methylation
Blood and either lip or palate tissue samples were avail-
able for each of the 150 children in this study. The
orofacial tissue type was dependent on the OFC subtype;
therefore, lip samples were available for children with
CLO and palate samples for children with CPO. Of the
50 children with CLP, 43 contributed a lip sample and
just seven contributed a palate sample. To allow us to
make pairwise comparisons between all three subtypes
using the same tissue type, we carried out our main ana-
lyses on blood samples.
Upon arrival at the Bristol Bioresource Laboratories
(BBL), whole-blood samples were immediately separated
by centrifugation into white blood cell and plasma aliquots
before storage at −80 °C. Lip/palate tissue samples were
stored at −80 °C in RNAlater. DNA from white blood cells
and tissue samples was extracted, and genome-wide DNA
methylation was measured using the Illumina Infinium
HumanMethylation450 BeadChip platform. Blood and
tissue samples were randomised over different batches.
Data were pre-processed in R version 3.3.2 with the
meffil package [28]. Functional normalisation [29] was
performed in an attempt to reduce the non-biological
differences between probes. Blood and tissue samples
were normalised together. Of the original 150 blood
samples, three failed quality control due to a mismatch
between reported and methylation-predicted sex (and
additional data from NHS Digital or parental question-
naire was not available to cross check). Of the original
150 lip/palate tissue samples, two lip samples failed
quality control due to assay failure.
Epigenome-wide association studies (EWAS) were
conducted using data from the blood as described below.
For these studies, we removed 944 probes that failed
quality control in meffil and a further 1058 probes that
had a detection P value >0.05 for >5% of samples. Fi-
nally, we removed 11,648 probes mapping to the X or Y
chromosomes and 65 SNP probes included on the array
for quality control purposes. This left 472,792 probes in
the dataset for the EWAS. Extreme outliers in the blood
and tissue methylation data were identified using the
Tukey method (<1st quartile−3 × IQR; >3rd quartile+3 ×
IQR) and set as missing. The median number of samples
removed per probe was 0 (IQR 0 to 1; range 0 to 72).
Methylation data were reported as beta values, ranging
from 0 (completely unmethylated) to 1 (completely
methylated).
Statistical analysis
We assessed the association between parental and child
characteristics and cleft subtype using chi-squared or t
tests. We also used linear regression to explore whether
‘epigenetic age’ (age predicted using the blood methyla-
tion data) differed from true age at sampling and
whether any deviation (age acceleration) was associated
with OFC subtype or any parental characteristics.
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Epigenome-wide association studies (EWAS) were
conducted in R version 3.3.2 [25]. For our main EWAS
analyses, we used linear regression to model cleft sub-
type as the exposure and untransformed blood methyla-
tion beta values as the outcome. To identify blood
methylation profiles specific to each subtype, we made
three pairwise comparisons: CPO compared to CLP
(CPOvsCLP), CLO compared to CLP (CLOvsCLP), CPO
compared to CLO (CPOvsCLO). All models were ad-
justed for sex because previous studies have found dif-
ferent sex ratios for OFC subtypes. In order to adjust for
technical batch effects and cellular heterogeneity, we cal-
culated surrogate variables and included these in all
models. We also conducted a sensitivity analysis using
chip ID to adjust for batch and Houseman-estimated cell
proportions to adjust for cellular heterogeneity. For the
results from the CPOvsCLO and the CPOvsCLP EWAS
analyses, we removed age-related CpGs as described
below. P values were corrected for multiple testing using
the Bonferroni method and a threshold of 0.05, i.e. an
uncorrected P value threshold of 1 × 10−7. Regression
coefficients are interpreted as the difference in mean
methylation beta value in children with one subtype
compared to children with another subtype.
In addition to the EWAS analyses at individual CpGs,
we also used Comb-P [30] to detect differential methyla-
tion across larger regions of the genome. This approach
is statistically more powerful and has been associated
with a lower rate of false positive findings compared to
EWAS at individual CpGs [31]. Using genomic location
and P values from our individual CpG EWAS results,
Comb-P identifies regions that are enriched for low P
values. It then calculates and adjusts for auto-correlation
between those P values using the Stouffer-Liptak-Kechris
correction and performs Sidak correction for multiple
testing. Differentially methylated regions (DMRs) were de-
fined as regions fulfilling these criteria: (1) contains at
least two probes, (2) all probes within the region are
within 1000 base pairs of at least one other probe in the
region, and (3) the Sidak-corrected P value for the region
is <0.05.
Special consideration of age at sampling
Biological samples were collected at first surgery, which
is typically around 3–6 months after birth for lip repair
and 6–18 months after birth for palate repair. Therefore,
we anticipated that the children with CLO and CLP
would be younger than the children with CPO. Previous
studies have shown that age, particularly during this
early developmental period, is strongly associated with
methylation [32–34]. We refrained from adjusting for
age at sampling because it is not a true confounder (it
cannot plausibly cause OFC subtype). Instead, we con-
sidered it a nuisance variable and dealt with it by
‘filtering out’ any age at sampling-related CpGs from our
main analysis. To do this, using all the participants in
our sample, we ran an EWAS of age at time of blood
sampling, and for any age-associated CpGs (uncorrected
P value <0.05), we set the EWAS P values from the
CPOvsCLP and the CPOvsCLO analyses to 1. This
meant that we were filtering out age-related CpGs from
our main EWAS results while maintaining the same
multiple testing burden and array structure for the
region-based analysis. In the age-at-sampling EWAS,
child’s age in months was modelled as the exposure with
methylation as the outcome. The model was adjusted for
10 surrogate variables for technical batch and cellular
heterogeneity. We confirmed that our age-at-sampling
EWAS was effectively identifying age-related CpGs
(independent of OFC subtype) by inspecting heterogeneity
statistics from a meta-analysis of three separate age-at-
sampling EWASs run within each OFC group (more
details in Additional file 1).
Functional analysis
To explore the function of any OFC-associated DMRs,
we used the missMethyl [35] R package to test for en-
richment of any gene ontology (GO) classification terms
or Kyoto Encyclopaedia of Genes and Genomes (KEGG)
pathways. This method corrects for biases in the genomic
coverage of the Illumina Infinium HumanMethylation450
BeadChip array. We also looked up gene annotations from
our DMRs in recently curated lists of OFC-related genes
from (1) the DisGeNET database of diseases and related
genes from human, rat and mouse studies [36] and (2) a
bioinformatics study of OFC-related genes in human and
animal studies published by Funato et al. [37].
Comparison to DNA methylation in lip/palate tissue
We postulated that DNA methylation in tissue at the
OFC site might most closely represent DNA methylation
in the developing orofacial tissues; therefore, we were in-
terested in the correlation between DNA methylation in
the blood and in tissue at the site of the OFC at our top
DMRs. We calculated within-subjects blood-tissue
Spearman’s rho correlation coefficients for each CpG in
each DMR. Correlation was assessed before and after
the methylation data were adjusted for the top ten prin-
cipal components (to capture cellular heterogeneity and
technical batch). To calculate principal components, the
methylation data were first split into separate datasets
for blood, lip and palate samples and the R function
prcomp was applied to the 10,000 most variable probes.
The methylation datasets were then adjusted for their
principal components using the Limma package [38] in
R. Additionally, we conducted an EWAS (in the same
way as described above in blood samples) to compare
CLO to CLP in lip samples. We did not conduct an
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EWAS of CPOvsCLP in palate tissue due to only having
seven palate samples for children with CLP. We did not
conduct an EWAS of CPOvsCLO in tissue because it
would be impossible to disentangle differences due to
OFC subtype from differences due to tissue.
Results
Characteristics of participants
From 150 participants selected for the study, 147 passed
quality control for blood and methylation data and 146
had information on all variables in the main model (sub-
type, age at sampling, sex). Participant characteristics are
summarised in Table 1. As we expected, children with
CPO were on average 4 months older than children with
CLO (t test P = 1.3 × 10−19) and 6 months older than
children with CLP (t test P = 35.8 × 10−14) because of the
timing of the surgery for the lip and palate repair (Fig. 2).
Accordingly, the same pattern was seen for epigenetic
age, despite the weak correlation with actual age (Spearman’s
rho for all participants 0.7; CPO 0.5, CLO 0.3, CLP
0.3). Participants with CLP tended to have a higher epi-
genetic age than their actual age (mean residual
0.8 months) whereas participants with CLO or CPO
tended to have a lower epigenetic age than their actual age
(mean residual −0.3 and −0.5, respectively). However, the
confidence intervals crossed the null and t test P values
for differences between subtypes were large (ranging 0.1
to 0.9). Age acceleration was also not associated with any
measured confounder (Additional file 1). Participants
with CLP were more likely to be male than participants
with CLO (chi-squared P = 0.02) or CPO (chi-squared
P = 0.002), but there was no difference in the sex ratio
between participants with CLO and CPO (chi-squared
P = 0.60). According to maternal self-report of smoking
behaviour, participants with CPO were more likely to
have mothers who smoked around the time of concep-
tion compared to participants with CLP and CLO (chi-
squared P value = 0.07). It should be noted that there
was a particularly high level of missing data for this
variable (70%). A tobacco exposure score calculated
Table 1 Participant characteristics
CLO (n = 49) CLP (n = 49) CPO (n = 49) P value*
Age in months at sample collection (95% CI) 4.1 (3.8, 4.4) 5.5 (4.7, 6.3) 11.2 (10.3, 12.0) 3.9 × 10−27
Epigenetic agea in months at sample collection (95% CI) 5.4 (4.2, 6.5) 8.7 (7.1, 10.3) 13.7 (11.9, 15.5) 5.0 × 10−11
Age accelerationb in months (95% CI) −0.3 (−1.5, 0.8) 0.8 (−0.1, 1.8) −0.5 (−2.0, 1.0) 0.23
Female (%) 19 (39%)
(1 missing)
8 (16%) 23 (47%) 0.004
White ethnicity (%) 25 (93%)
(22 missing)
27 (93%)
(20 missing)
23 (88%)
(23 missing)
0.80
Maternal age at conception (95% CI) 30.9 (29.4, 32.4) 29.4 (27.9, 30.9) 31.1 (29.8, 32.4) 0.21
Paternal age at conception (95% CI) 34.1 (32.2, 35.9) 32.7 (30.8, 34.7) 35.3 (33.4, 37.1) 0.23
Methylation-predicted tobacco exposure score (95% CI) 0.004 (−0.1, 0.1) −0.1 (−0.2, 0.1) 0.1 (−0.1, 0.2) 0.361
Self-reported maternal smoking around conception (%) 0 (0%)
(33 missing)
4 (36%)
(38 missing)
7 (44%)
(33 missing)
0.01
Maternal education: university degree or higher (%) 13 (48%)
(22 missing)
13 (48%)
(22 missing)
15 (58%)
(23 missing)
0.73
Maternal occupation: non-manual work 10 (38%)
(23 missing)
13 (50%)
(23 missing)
14 (61%)
(26 missing)
0.29
Parity > =1 12 (43%)
(21 missing)
19 (66%)
(20 missing)
11 (46%)
(25 missing)
0.18
*P values were calculated using either ANOVA or chi-squared/Fishers tests
aEpigenetic age is age predicted using DNA methylation as described in Horvath et al. [20]
bAge acceleration refers to the residuals from a linear regression of epigenetic age on actual age as described in Horvath et al. [20]
Fig. 2 Age at sampling and OFC subtype. Children with CPO were
older on average than children with CLO or CLP because surgery for
palate repair usually occurs later than surgery for lip repair
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from the blood DNA methylation data was not associ-
ated with cleft subtype (chi-squared P = 0.361).
Individual CpG epigenome-wide study in blood
After the Bonferroni correction for multiple testing,
there were no CpGs where blood DNA methylation was
associated with either CLO (n = 48) compared to CLP
(n = 49) or CPO (n = 49) compared to CLP (P > 1 × 10−7).
In contrast, 335 CpGs were associated with CPO com-
pared to CLO (Additional file 2, Table S1). Sensitivity ana-
lyses adjusting for chip ID and Houseman-estimated cell
types (instead of surrogate variables) did not yield sub-
stantially different results (Additional file 1). We consid-
ered that some of these associations might be better
explained by differences in age than OFC subtype, so
we compared the results to those of our EWAS of age
at sampling (described above). There were 29,984 CpGs
associated with age at sampling with an uncorrected P
value <0.05 (N participants in analysis 139; Additional
file 2 Table S2). Confidence that these CpGs are truly
associated with age (independently of OFC subtype)
comes from our observation of low heterogeneity when
we meta-analysed three separate age-at-sampling
EWAS run within each OFC group (more details in
Additional file 1) and the fact that many of these CpGs
have previously been shown to be differentially methylated
with age in infancy [33]. Of the 29,984 age-associated
CpGs, 214 were also associated with CPO compared to
CLO with P < 1 × 10−7. When we ‘filtered out’ the 29,984
age-related CpGs by setting the P values to 1 in the
CPOvsCLP and CPOvsCLO results, 121 CpGs were asso-
ciated with CPO compared to CLO (P value <1 × 10−7;
Table 2; Additional file 2 Table S1). All subsequent ana-
lyses were performed on these results, that is, CLOvsCLP
without filtering age-associated CpGs, and CPOvsCLP
and CPOvsCLO with age-associated CpGs filtered. Full
Table 2 CpGs associated with CPO compared to CLO in the single-site EWAS analysis after filtering out age-related CpGs
Chr CpG Regression coefficient P value Gene Relation to CpG island Relation to gene
19 cg01634146 0.19 9.80 × 10−13 NFIX S_Shelf Body
22 cg12899065 0.16 3.98 × 10−8 GP1BB;SEPT5 Island TSS1500;3′UTR
6 cg14623715 0.14 2.46 × 10−10 PDE7B Body
10 cg02017450 −0.14 5.93 × 10−11 intergenic [SFTA1P]
8 cg04364695 −0.13 4.27 × 10−8 ZMAT4 Body
7 cg22114489 −0.13 4.60 × 10−8 intergenic [CUX2]
1 cg12697139 −0.13 2.23 × 10−11 intergenic [MIR205HG]
2 cg19075787 −0.13 8.44 × 10−9 intergenic [LOC284998]
11 cg17696044 −0.13 8.61 × 10−8 SHANK2 Body
20 cg19592472 −0.12 5.04 × 10−8 OXT Island 1stExon;5′UTR
4 cg14348967 −0.12 5.12 × 10−9 intergenic [DQ599898]
6 cg00257775 −0.12 9.45 × 10−10 ZFAND3 Body
3 cg25938530 −0.11 2.04 × 10−8 ITIH1 TSS200;Body
11 cg12155547 −0.11 9.96 × 10−12 intergenic [NEAT1] S_Shelf
1 cg18147098 0.11 5.44 × 10−8 intergenic [ATF3] S_Shore
8 cg19496364 0.10 1.16 × 10−8 intergenic [LINC00535]
7 cg27508620 0.10 3.67 × 10−8 intergenic [SP4]
6 cg25426302 0.10 9.90 × 10−8 PPT2;PRRT1 N_Shore TSS1500
10 cg20327845 −0.10 6.66 × 10−8 PFKP Body
3 cg05581878 −0.10 2.50 × 10−9 intergenic [AK097161]
10 cg19220719 −0.10 7.02 × 10−9 intergenic [C10orf11]
22 cg13251842 0.09 6.67 × 10−8 MIRLET7A3;MIRLET7B TSS200; TSS1500
19 cg27392771 0.09 5.25 × 10−15 NFIX S_Shore Body
6 cg23279756 −0.09 7.14 × 10−8 intergenic [ARMC2]
2 cg07644939 0.09 3.12 × 10−10 SNED1 S_Shore Body
The top 25 CpGs with the largest effect sizes and P values <1 × 10−7 are shown. For intergenic regions, the closest annotated gene is shown in square brackets
S_Shore South shore, S_Shelf South shelf, N_Shore North shore, TSS1500 1500 base pairs from a transcription start site; TSS200 200 base pairs from a transcription
start site, UTR untranslated region
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blood EWAS results for all three OFC subtype compari-
sons are available as additional files (Additional files 3, 4
and 5) and summarised in Fig. 3.
Differentially methylated region analysis of blood EWAS
results
When we interrogated differential methylation over lar-
ger regions of the genome, we found four DMRs in CLO
compared to CLP, 17 in CPO compared to CLP and 294
in CPO compared to CLO (Sidak-corrected P value <0.05;
Additional file 2 Table S3). The top DMRs with Sidak P
values <0.05 and the largest regression coefficients
(taken from the single-site EWAS) are presented in
Table 3. Boxplots of methylation levels averaged over
the top DMRs for each subtype comparison are shown
in Fig. 4.
None of the 25 CpGs in the four CLOvsCLP DMRs
overlapped with CpGs in DMRs from the other two
comparisons. Of the 82 CpGs in the 17 CPOvsCLP
DMRs, 39 (48%) were also in the list of 1063 CpGs in
the 294 CPOvsCLO DMRs (Fig. 5). CPO was associated
with higher methylation relative to CLP or CLO at 18 of
these 39 CpGs and lower methylation relative to CLP or
CLO at the remaining 21/39 CpGs.
Functional analysis of DMRs
There was no enrichment (FDR-adjusted P value <0.05)
for any functional categories defined using GO terms or
KEGG pathways in CpGs within CLOvsCLP DMRs or
CPOvsCLP DMRs. CpGs in CPOvsCLO DMRs were
also not enriched for any GO terms, but were enriched
for 66 KEGG pathways. However, these were mostly
broad (for example, pathways in cancer, MicroRNAs in
cancer, fatty acid metabolism). The top five KEGG and
GO terms with the smallest P values for each list of
CpGs in DMRs are presented in Additional file 2 Table S4.
According to the DisGeNET database, there were 286
genes associated with OFCs, of which 93 were also iden-
tified in a recent bioinformatics study [37] that found
357 unique OFC-related genes (total number of OFC-
related genes from the literature, 643; Additional file 2
Table S5). Of these, eight mapped to regions that were
differentially methylated in CPO compared to CLO, and
two mapped to regions that were differentially methyl-
ated in CPO compared to CLP in our study. These genes
are detailed in Table 4.
Comparison to DNA methylation in lip/palate tissue
We were interested in the correlation between DNA
methylation in the blood and in the tissue at the site of
the OFC at our top DMRs. The within-subjects correl-
ation between DNA methylation in the blood and in ei-
ther lip or palate tissue was higher at CpGs in DMRs
than CpGs in other regions of the genome (Table 5;
Mann-whitney U P values for difference in median rhos,
blood vs lip 1.6 × 10−34, blood vs palate 5.5 × 10−18).
In an EWAS of CLO (n = 48) compared to CLP (n = 43)
in lip tissue (the only EWAS we were able to conduct in
tissue samples), there was no single CpG with a
Bonferroni-adjusted P value <0.05 (P > 1 × 10−7). However,
there were 14 DMRs containing a total of 77 CpGs
(Additional file 2, Table S3). This included one inter-
genic region near KIAA0415 that was around 4% more
methylated in children with CLO compared to children
with CLP in both the blood and lip tissue. The top
DMRs with Sidak P values <0.05 and the largest regres-
sion coefficients (taken from the single-site EWAS) are
presented in Table 3.
Discussion
In this, the first study epigenetic epidemiological study
of OFCs, we found multiple genomic regions differentially
methylated in blood samples from non-syndromic chil-
dren with CLO, CLP and CPO. Many more regions were
differentially methylated between CPO and CLO than be-
tween CPO and CLP, and more regions were differentially
methylated between CPO and CLP than between CLO
and CLP. This suggests that all three subtypes have dis-
tinct DNA methylation profiles, but the DNA methylation
profiles of CLO and CLP are more similar to each other
than the DNA methylation profile of CPO. This has im-
portant implications for OFC research, reminding us that
CLO, CLP and CPO should be analysed separately and
not combined into a single entity or CL/P for analysis, as
is sometimes the case in epidemiological and genetics
studies.
Ideally, we would have compared methylation profiles
in children with an OFC to those of children of a similar
age without any congenital anomalies. However, the
Cleft Collective cohort is a case-only cohort, so an ap-
propriate control group was not available. We explored
several options for controls from other cohorts, includ-
ing from publicly available data, but did not identify any
options that would not have introduced significant con-
founding/bias by factors such as technical batch, age, tis-
sue or population. In fact, when we attempted to
compare our children with OFCs to blood DNA methy-
lation from children in two publicly available datasets
(Gene Expression Omnibus accession numbers: GSE62219
[33] and GSE67444 [39]), we found substantial inflation
and tens of thousands of differentially methylated CpGs, in-
dicating insurmountable confounding (methods and results
described in more detail in Additional file 1). Despite the
lack of controls, our finding of distinct DNA methylation
profiles in subtypes of OFCs is an important first step and
highlights the need for more studies to explore the poten-
tial role of epigenetic modifications in either causing or pre-
dicting different types of OFC.
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Fig. 3 Manhattan plots of the three pairwise epigenome-wide studies of DNA methylation in whole-blood samples from children with CLO,
CLP and CPO. P values for age-related CpGs have been set to 1 (i.e. −log10 P value of 0) in the comparisons involving CPO. The red line
indicates the threshold where P = 1 × 10−7 (i.e. a Bonferroni-corrected P value of 0.05)
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We consider three main possible explanations for why
children with different OFC subtypes have different
blood DNA methylation profiles.
Firstly, the subtypes might have distinct aetiologies in
which DNA methylation plays a mechanistic role, i.e. the
subtypes are caused, in part, by differences in DNA
methylation. For this to be the case, blood DNA methy-
lation at the time of sampling (up to 20 months after
birth) would have to closely reflect DNA methylation in
the developing orofacial tissues during embryogenesis.
Although this is plausible, particularly at metastable epi-
alleles where variable DNA methylation is established
early in development before cellular differentiation, we
did not have sufficient data to explore this possibility.
For obvious ethical reasons, it is not possible to study
embryonic tissues in humans; however, we were able to
study methylation levels in lip and palate tissue collected
postnatally at the time of surgery. We postulated that
postnatal orofacial tissues might reflect embryonic orofa-
cial tissues more closely than blood. We calculated the
within-subjects correlation at CpGs in DMRs identified
in the blood EWAS. On average, correlations between
blood and lip/palate were higher in regions that were as-
sociated with OFC subtype than regions that were not.
This suggests that methylation at some of the sites we
identified as being differentially methylated in blood
Table 3 Top five DMRs with the largest regression coefficients and Sidak-corrected P values <0.05
EWAS DMR Genea N CpGs Sidak-corrected P value Range of regression coefficients
CLOvsCLP
(blood)
Chr6:160241105-160241557 PNLDC1 4 4.8 x 10−4 0.053, 0.078
CLOvsCLP
(blood)
Chr8:124194847-124195193 FAM83A 5 1.3 x 10−3 −0.072, −0.007
CLOvsCLP
(blood)
Chr6:33280052-33280437 TAPBP 11 2.8 x 10−5 −0.049, −0.008
CLOvsCLP
(blood)
Chr7:4832112-4832536 Intergenic
[KIAA0415]
5 8.6 x 10−4 0.023, 0.059
CPOvsCLP
(blood)
Chr22:46508451-46508605 MIRLET7A3 6 8.07 x 10−7 0.028, 0.119
CPOvsCLP
(blood)
Chr17:80541737-80542119 FOXK2 4 1.05 x 10−6 0.060, 0.079
CPOvsCLP
(blood)
Chr10:101282726-101283091 Intergenic
[DQ372722]
5 7.23 x 10−7 0.026, 0.077
CPOvsCLP
(blood)
Chr16:55866757-55867073 CES1 5 9.67 x 10−5 −0.093, −0.066
CPOvsCLP
(blood)
Chr22:51016501-51017152 CPT1B 12 1.47 x 10−7 −0.063, −0.026
CPOvsCLO
(blood)
Chr22:19709548-19710164 GP1BB 5 1.23 x 10−14 0.067, 0.162
CPOvsCLO
(blood)
Chr22:46508451-46508605 MIRLET7A3 6 1.51 x 10−14 0.035, 0.142
CPOvsCLO
(blood)
Chr7:101398152-101398185 Intergenic [CUX1] 3 3.00 x 10−13 −0.131, −0.085
CPOvsCLO
(blood)
Chr1:212688417-212688998 Intergenic [ATF3] 6 1.23 x 10−16 0.018, 0.108
CPOvsCLO
(blood)
Chr7:90895894-90896702 FZD1 4 1.07 x 10−9 0.114, 0.170
CLOvsCLP
(lip)
Chr7:158789723-158790116 LOC154822 4 4.3 x 10−3 −0.084, −0.045
CLOvsCLP
(lip)
Chr6:161796785-161796855 PARK2 3 1.4 x 10−2 −0.073, −0.050
CLOvsCLP
(lip)
Chr1:248100183-248100615 OR2L13 10 4.1 x 10−5 0.027, 0.087
CLOvsCLP
(lip)
Chr7:4832112-4832536 KIAA0415 5 5.8 x 10−4 −0.029, 0.043
CLOvsCLP
(lip)
Chr1:7842159-7842407 VAMP3 4 1.8 x 10−4 −0.027, −0.055
aFor intergenic regions, the closest annotated gene is shown in square brackets.
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correspond to methylation in the postnatal orofacial tis-
sues, which is arguably a more relevant tissue in which
to study the role of methylation in causing OFCs. How-
ever, we note that the huge changes in tissue structure
and function during development mean that our as-
sumption that postnatal orofacial methylation might ac-
curately reflect embryonic methylation could be
incorrect.
Fig. 4 Blood DNA methylation levels at the top differentially methylated regions. DMRs were selected based on largest effect size and a Sidak-
corrected P value <0.05 for each pairwise epigenome-wide study in blood
Sharp et al. Clinical Epigenetics  (2017) 9:63 Page 10 of 17
Secondly, the subtypes might have distinct aetiologies
explained by genetic and/or environmental factors that
also influence blood DNA methylation. That is, the asso-
ciation between OFC subtype and DNA methylation is
confounded by genotype or prenatal environmental fac-
tors such as maternal smoking or obesity. Correlations
between blood and lip/palate methylation could be ex-
plained by genetic and/or environmental factors that
affect methylation in disparate tissues in the same way.
Regardless of whether or not DNA methylation plays a
mechanistic role, our finding of distinct blood DNA
methylation profiles between subtypes suggests that
DNA methylation could potentially be developed into a
useful biomarker for different OFC subtypes. Such a bio-
marker could be used to predict OFC subtype in studies
where data is missing, poor or requires cross-validation.
It could also be used clinically to improve diagnosis of
OFCs and thereby reduce the rate of poor outcomes as-
sociated with late diagnosis of CPO. Methylation is on a
continuous scale and might therefore be able to capture
phenotypes such as submucosal OFCs more accurately
than current clinical classifications. Further work is war-
ranted to explore whether OFC-associated DNA methy-
lation in infancy is associated with later surgical, health,
developmental and psychological outcomes. If so, a
DNA methylation-based biomarker for OFC subtype
might be useful in identifying individuals who may de-
velop poorer outcomes and benefit from more intensive
monitoring and/or therapy.
Thirdly, since OFCs form early in embryonic devel-
opment and blood DNA methylation was measured in
infancy, it is possible that the OFC subtype could
Fig. 5 A Venn diagram to show the crossover in CpGs within DMRs
associated with each subtype comparison. Arrows show the direction
of association, i.e. hyper- (up) or hypo- (down) methylation
Table 4 Blood DMRs where genetic variation has previously been associated with OFCs
Gene DMR Sidak-corrected
P value
Findings in
this study
N CpGs
in DMR
Example of previous findings
TBX1c Chr22:19750918-19752870
Chr22:19736256-19736672
1.61 × 10−10
5.03 × 10−4
↑ in CPO
vs CLO
↑ in CPO
vs CLO
6
2
Variants were associated with non-syndromic CL/P in a
candidate gene study of a Brazilian population [41]
COL11A2c Chr6:33132086-33132728 2.13 × 10−9 ↑ in CPO
vs CLO
15 Multiple haplotypes have been associated with non-syndromic
CPO compared to unaffected individuals [44]
HOXA2b Chr7:27143046-27143807
Chr7:27143235-27143586
1.04 × 10−7
3.9 × 10−2
↑ in CPO
vs CLO
↑ in CPO
vs CLP
7
7
Hoxa-2 mutant mice have abnormal palatogenesis [71, 72]
CRB2a Chr9:126130901-126131310 5.14 × 10−4 ↑ in CPO
vs CLO
2 Several non-syndromic CL/P susceptibility genes have been
identified in the 9q22.32–34.1 region that includes CRB2 [73]
PDGFRAc Chr4:55090812-55091179 2.71 × 10−2 ↑ in CPO
vs CLO
2 Mutations in PDGFRA have been associated with non-syndromic
CPO [74]
CRISPLD2
c
Chr16:84870066-84870204 3.41 × 10−2 ↑ in CPO
vs CLO
2 Variants have been associated with non-syndromic CL/P, with
some evidence for rs1546124 being associated with CPO in
several populations [75]
SMOC1c Chr14:70316898-70317240 1.39 × 10−5 ↓ in CPO
vs CLP
5 A significant proportion of Smoc1 homozygous mutant mice
have cleft palate [76]
PVRL1c Chr11:119630144-119630363 1.52 × 10−5 ↓ in CPO
vs CLO
2 Rare and common mutations within PVRL1 were associated
with non-syndromic CLP in a family-based study of multiple
populations [77]
CCL2a Chr17:32582128-32582829 3.00 × 10−4 ↓ in CPO
vs CLO
6 Variants mapping to CCL2 were associated with non-syndromic
CL/P in a candidate gene study [78]
aIdentified as OFC-related in DisGeNET
bIdentified as OFC-related in Funato et al.
cIdentified as OFC-related in both
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indirectly influence blood DNA methylation, that is,
any association between OFC subtype and DNA
methylation could be explained by reverse causation.
For (hypothetical) example, children with CPO or CLP
might have more difficulty feeding compared to children
with CLO and the subsequent different nutritional expos-
ure may cause differences in DNA methylation between
children with these subtypes. If DNA methylation in in-
fancy is influenced by OFC subtype and/or severity, then
methylation could be a useful predictor of downstream
OFC outcomes (as discussed above). The Cleft Collective
is currently collecting cord blood samples, which are un-
affected by postnatal environmental factors, and will
therefore help us explore the direction of any causal effect
between DNA methylation and OFC subtypes.
Further work is warranted to explore our findings in a
causal analysis framework. However, several of our
DMRs map to genes that have previously been associ-
ated with OFCs, which provides some support that DNA
methylation at these genes either plays a causal role in
development of OFC subtypes or reflects different gen-
etic or environmental factors that do. For example, we
identified six CpGs in a region on the gene body of
TBX1 that were 3 to 8% more highly methylated in
blood DNA from children with CPO compared to CLO.
TBX1 encodes the T-box transcription factor 1 and dele-
tion of this region causes chromosome 22q11.2 deletion
syndrome, characterised by, amongst other malforma-
tions, cleft palate [40]. Genetic variants at TBX1 have
also been associated with non-syndromic CL/P [41].
Tbx1 is expressed on the palatal shelves in mice and de-
letion results in abnormal epithelial fusion [42]. We also
identified a region of 15 CpGs on the gene body of
COL11A2 that were around 2% more highly methylated
in CPO than CLO. COL11A2 is one of three distinct
genes that encode collagen XI, which is expressed in
the developing jaw in rats [43]. Genetic variants in
COL11A2 can cause syndromic and non-syndromic pal-
atal defects [44, 45].
Amongst our identified DMRs, there were some add-
itional gene-OFC relations that have previously been re-
ported in the literature, but that were not included in
either the DisGeNET database or the recent review of
OFC genes by Funato et al. [37]. For example, rare and/or
common variants have been associated with non-syndromic
CL/P at regions that were differentially methylated in
CPOvsCLO: FZD1 (hypermethylated) [46], VAX2
(hypermethylated) [47] and FGF12 (hypomethylated)
[48]. We also found that children with CPO had lower
methylation than children with CLO at a region of five
CpGs near MKNK2, which has very recently been asso-
ciated with non-syndromic CL/P in central Europeans
[49]. However this DMR did not survive correction for
multiple testing (Sidak-corrected P = 0.2). Our finding
of DMRs near OFC-implicated genes is consistent with
the hypothesis that these loci play an important part in
OFC aetiology, with two possible explanations for the
observed associations: (1) they are explained by the
underlying genetic architecture (and some of the chil-
dren in our study may have undiagnosed syndromes
caused by these genes); (2) they are explained by non-
genetic variation in DNA methylation that had a causal
effect on the development of the orofacial region and is
also detectable in infant blood. Either way, these obser-
vations corroborate that perturbation of gene function
at these loci is important in causing OFCs.
We also found over 250 novel genomic regions associ-
ated with different OFC subtypes, including four and 14
regions differentially methylated in CLO compared to
CLP in blood and lip tissue, respectively. One region,
near KIAA0415, was differentially methylated in both
the blood and lip, with strikingly similar regression coef-
ficients at the seven CpGs in the region (median for the
blood 0.045 [IQR 0.039, 0.051], median for the lip 0.042
[IQR 0.031, 0.043]). This is perhaps more indicative of
an underlying genetic effect rather than a direct associ-
ation with methylation. Few genes have previously been
implicated in CLO, because most studies have not con-
sidered it as molecularly distinct from CLP.
Of the novel genes associated with CPOvsCLO or
CPOvsCLP in the blood, we have selected a few that
could be related to OFCs via a biologically plausible
mechanism. For example, we found a region of six CpGs
near MIRLET7A3 that was 8% more highly methylated
in CPO compared to CLO and 5% more highly methyl-
ated in CPO compared to CLP. MIRLET7A3 encodes a
microRNA precursor, and although the mechanistic role
of microRNAs in human OFCs has not been fully ex-
plored, there is some evidence from mouse studies that
they could be important [50]. Furthermore, a recent
microarray study found that has-let-7a-5p, which is the
mature sequence of the MIRLET7A3-encoded precursor,
was overexpressed in plasma samples from non-syndromic
children with CPO and CLP relative to unaffected controls
[51]. In our CPOvsCLO comparison, we also found several
novel DMRs mapping to genes that have previously been
linked to neural tube closure and/or defects (NTDs), for
example RGMA [52], ARHGEF1 [53] and NODAL [54], as
well as two genes that have been linked to both OFCs
and NTDs, CCL2 [55] and PDGFRA [56]. This is par-
ticularly interesting, because NTDs and OFCs appear
to share some aetiological features: they both occur
when tissues in the midline fail to fuse completely
during embryonic development [57]; they co-occur in
the same individuals and in related individuals more
than would be expected by chance [58]; they share
several environmental risk factors [2, 3, 59, 60]. Our
findings further support recent evidence of an overlap
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in the molecular networks associated with OFCs and
NTDs [61].
Finally, two of the DMRs we identified have previously
been found in association with maternal risk factors for
OFCs. A region of four CpGs at HIF3A was between 3
and 15% more highly methylated in children with CPO
than in children with CLO. Methylation in this region
has previously been associated with measures of adiposity,
most commonly body mass index (BMI) [62]. A previous
study found a positive association between maternal BMI
and offspring cord blood DNA methylation at the four
CpGs in our HIF3A DMR [63]. Additionally, a region of
two CpGs at PRPH was 5% more highly methylated in
children with CPO than in children with CLO. Methyla-
tion at three (different) CpGs at PRPH has previously been
negatively associated with maternal plasma folate levels
[64]. These findings might indicate distinct aetiologies
with different risk factors, suggesting that CPO and CLO
are differentially influenced by maternal adiposity and/or
maternal folate levels.
Although OFCs are one of the most common birth de-
fects, they are relatively rare, so collecting data on large
numbers of affected individuals is challenging [17]. We
used data and samples collected as part of the Cleft Col-
lective cohort study, which is a unique and valuable re-
source for OFC research. The prospective nature of this
cohort means that future work can assess whether the
subtype-associated methylation we see in infancy persists
to later ages and is associated with longer term adverse
outcomes of OFC such as poor educational attainment.
Partly due to the novelty of these data and this resource,
we were unable to find an independent cohort with simi-
lar data to replicate our findings. We hope to generate
DNA methylation data for a larger sample of Cleft Col-
lective children and test for replication in future studies.
We also hope to use a larger sample to develop and ex-
plore the utility of a biomarker to predict OFC subtype.
Another potential limitation of our study is that chil-
dren with CPO were on average 6 to 7 months older
than children with CLO and CLP, which had a large in-
fluence on the results of the EWAS comparing these
subtypes. Although we believe we were largely successful
in our attempt to remove this influence by filtering out
age-related CpGs using a very liberal P value threshold
of uncorrected P < 0.05, there may be some residual in-
fluence. For example, three of the top 25 CpGs where
there is most evidence of differential methylation be-
tween CPO and CLO (Table 2) map to two genes that
have previously been reported as associated with gesta-
tional age and/or age in infancy: NFIX [32, 33, 65] and
SNED1 [33]. However, a previous microarray study of lip
tissue found lower expression of NFIX in children with
CLP compared to children with CLO even though both
groups were sampled at 4-months-old, which provides
some evidence that NFIX may be associated with OFCs
independently of age [66]. Differences in the surgical
protocol for lip and palate repair mean that this limita-
tion (of age differences between children with CPO and
CL/P) is likely to be present in other studies of OFCs
where samples are collected at surgery, so techniques
such as the one described in this paper should be devel-
oped to attempt to overcome this. We found no evi-
dence of association between epigenetic age acceleration
and OFC subtypes. Previous studies have postulated that
epigenetic age acceleration is a measure of development
in children [67, 68], with a positive value indicating a
child who is developmentally advanced for their actual
age. Therefore, our finding of no association suggests
that children with different OFC subtypes have similar
rates of development.
The Cleft Collective cohort is still in the recruitment
stage, and genotype and gene expression data do not yet
exist for the participants. This means that we were not
able to infer causality between OFC subtypes and blood
DNA methylation using the Mendelian randomization
[69, 70] or explore functionality by calculating correla-
tions between methylation and expression. This is some-
thing we hope to do in further studies.
There was a high proportion of missing demographic
data (for example, on maternal smoking, education, oc-
cupation, ethnicity and parity), which is also related to
the Cleft Collective cohort being in its infancy. Partici-
pants selected for this study were recruited near the start
of the recruitment phase when questionnaire return
rates were lower. Our return rates have increased re-
cently and in future work, we hope to generate methyla-
tion data for a larger sample of the cohort with more
complete questionnaire data. In future studies, we hope
to have sufficient data to explore more potential con-
founders of the methylation-subtype associations.
Finally, as mentioned above, we were unable to make
comparisons with unaffected children because the Cleft
Collective is a case-only cohort and we could not identify
an appropriate control group that would not have in-
troduced substantial confounding. When genotype data
are available, future studies using the Mendelian
randomization will be able to circumvent these issues
with confounding. Additionally, the Cleft Collective is
collecting data on unaffected siblings, who we hope will
act as a good control sample in future studies.
Conclusions
In conclusion, we found several genomic regions differen-
tially methylated in blood and lip samples from non-
syndromic children with CLO, CLP and CPO. Confidence
in our results comes from the fact that some of these
genes have been previously linked to OFCs, but we
have also highlighted many novel regions. Our findings
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represent a promising first step in exploring the poten-
tial role of epigenetic modifications in the aetiology of
OFCs and/or as clinically useful biomarkers of different
types of OFC.
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